| J07CA06 |
Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IPV) and Haemophilus type b (Hib) conjugate vaccine (adsorbed). |
J07CA06 Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IPV) and Haemophilus type b (Hib) conjugate vaccine (adsorbed). |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| J07CA06 |
diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B |
Infanrix Hexa |
Powder and suspension for suspension for injection |
suspension: 0.5 ml |
|
1 vial + 1 prefilled syringe + 2 needles |
GlaxoSmithKline Biologicals S.A., Белгия |
1 |
dose |
71.27 |
71.27 |
71.27 |
100% |
|
Съгласно РУ |
КЦРР-2406/21.02.2013 г.; НСР-7707/17.12.2015 |
02.02.2016 |
08.09.2012 |
Активен |
1754 |
| J07CA09 |
diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B |
Infanrix Hexa |
Powder and suspension for suspension for injection |
suspension: 0.5 ml |
|
10 vials + 10 prefilled syringes |
GlaxoSmithKline Biologicals S.A., Белгия |
1 |
dose |
857.98 |
71.27 |
712.7 |
100% |
|
Съгласно РУ |
НСР-4827/14.10.2014 |
02.02.2016 |
|
Активен |
3213 |
| J07CA09 |
Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed) |
J07CA09 Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| J07CA09 |
diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B |
Hexacima |
Suspension for injection |
0,5 ml |
|
1 pre-filled syringe + 2 needles |
Sanofi Pasteur S.A., Франция |
1 |
dose |
72.01 |
72.01 |
72.01 |
100% |
|
Съгласно РУ |
НСР-3659/29.05.2014; НСР-5521/29.01.2015.; НСР-8627/31.03.2016. |
02.05.2016 |
|
Активен |
3537 |
| J07CA09 |
diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B |
Hexacima |
Suspension for injection |
0,5 ml |
|
10 vials (glass) |
Sanofi Pasteur S.A., Франция |
1 |
dose |
1232.44 |
72.01 |
720.1 |
100% |
|
Съгласно РУ |
НСР-4954/27.10.2014 |
02.05.2016 |
|
Активен |
3228 |
| L01AA01 |
Ciyclophosphamide |
L01AA01 Ciyclophosphamide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| L01AA01 |
Cyclophosphamide |
ENDOXAN |
Powder for solution for injection |
200 |
mg |
10 |
Baxter Oncolcogy GmbH, Германия |
1 |
mg |
51.74 |
0.02587 |
51.74 |
100% |
|
Съгласно РУ |
№ 42/ 04.01.2010 г.; КЦРР-2309/20.02.2013 г. |
02.03.2014 |
08.09.2012 |
Активен |
1666 |
| L01AA01 |
Cyclophosphamide |
ENDOXAN |
Powder for solution for injection |
500 |
mg |
1 |
Baxter Oncolcogy GmbH, Германия |
1 |
mg |
4.84 |
0.00968 |
4.84 |
100% |
|
Съгласно РУ |
№ 42/ 04.01.2010 г.; КЦРР-2309/20.02.2013 г; НСР-2722/06.02.2014 |
02.03.2014 |
08.09.2012 |
Заличен |
1667 |
| L01AA02 |
Chlorambucil |
L01AA02 Chlorambucil |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| L01AA02 |
Chlorambucil |
Leukeran |
Film coated tablet |
2 |
mg |
25 |
Aspen Pharma Trading Limited, Ирландия |
1 |
mg |
119.77 |
2.3954 |
119.77 |
100% |
|
Съгласно РУ |
НСР-7754/28.12.2015. |
02.01.2016 |
|
Активен |
4160 |
| L01AA06 |
Ifosfamide |
L01AA06 Ifosfamide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| L01AA06 |
Ifosfamide |
HOLOXAN |
Powder for solution for injection |
1000 |
mg |
1 |
Baxter Oncolcogy GmbH, Германия |
1 |
mg |
47.21 |
0.04721 |
47.21 |
100% |
|
Съгласно РУ |
№ 42/ 04.01.2010 г.; НСР-3194/07.04.2014; КП-104/03.11.2014 г.; КП-118/ 18.12.2014. |
16.01.2015 |
08.09.2012 |
Активен |
4054 |
| L01AA09 |
Bendamustine hydrochloride |
L01AA09 Bendamustine hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| L01AA09 |
Bendamustine |
Bendamustine Actavis |
Powder for concentrate for solution for infusion |
2.5 mg/ ml |
mg |
60 ml (100 mg) x 1 |
Actavis Group PTC ehf., Исландия |
1 |
mg |
514.49 |
4.24334 |
424.33 |
100% |
|
Съгласно РУ |
НСР-6438/12.06.2015. |
02.02.2016 |
|
Активен |
4013 |
| L01AA09 |
Bendamustine |
Bendamustine Sandoz |
Powder for concentrate for solution for infusion |
2.5 mg/ ml |
mg |
100 mg x 5 |
Sandoz d.d., Словения |
1 |
mg |
2121.67 |
4.24334 |
2121.67 |
100% |
|
Съгласно РУ |
НСР-7722/17.12.2015 |
02.02.2016 |
|
Активен |
4163 |
| L01AA09 |
Bendamustine |
Levact |
Powder for concentrate for solution for infusion |
2,5 mg/ml (25 mg) |
|
5 |
Astellas Pharma GmbH, Германия |
1 |
mg |
770.03 |
4.24334 |
530.42 |
100% |
|
Съгласно РУ |
НСР-6015/09.04.2015.; НСР-9638/23.06.2016г.; НСР-11708/10.02.2017 г. |
02.03.2017 |
|
Заличен |
3809 |
| L01AA09 |
Bendamustine |
Levact |
Powder for concentrate for solution for infusion |
2,5 mg/ml (100 mg) |
|
5 |
Astellas Pharma GmbH, Германия |
1 |
mg |
3002.74 |
4.24334 |
2121.67 |
100% |
|
Съгласно РУ |
КЦРР-1537/25.10.2012 г.; КП-219/11.05.2015 и НСР-5505/23.01.2015; НСР-10329/15.09.2016 |
02.11.2016 |
|
Активен |
3893 |
| L01AA09 |
Bendamustine |
Lynetoril 2,5 mg/ml |
Powder for concentrate for solution for infusion |
25 mg |
mg |
5 |
Chiesi Pharmaceuticals GmbH, Австрия |
1 |
mg |
769.14 |
4.24334 |
530.42 |
100% |
|
Съгласно РУ |
НСР-5281/ 18.12.2014; НСР-8322/26.02.2016; НСР-9055/21.04.2016 |
02.06.2016 |
|
Заличен |
3452 |
| L01AA09 |
Bendamustine |
Lynetoril 2,5 mg/ml |
Powder for concentrate for solution for infusion |
100 mg |
mg |
5 |
Chiesi Pharmaceuticals GmbH, Австрия |
1 |
mg |
2574.92 |
4.24334 |
2121.67 |
100% |
|
Съгласно РУ |
НСР-5247/10.12.2014. |
02.02.2016 |
|
Активен |
3442 |
| L01AD01 |
Carmustine |
L01AD01 Carmustine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| L01AD01 |
Carmustine |
BiCNU |
Powder for solution for injection |
100 |
mg |
1 |
Bristol-Myers Squibb Kft, Унгария |
1 |
mg |
59.81 |
0.5981 |
59.81 |
100% |
|
Съгласно РУ |
НСР-1937/06.12.2013; НСР-3617/29.05.2014 |
02.07.2014 |
08.09.2012 |
Заличен |
2445 |
| L01AD02 |
Lomustine |
L01AD02 Lomustine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| L01AD02 |
Lomustine |
CCNU |
Capsule, hard |
40 |
mg |
20 |
Bristol-Myers Squibb Kft, Унгария |
1 |
mg |
210.6 |
0.26325 |
210.6 |
100% |
|
Съгласно РУ |
КЦРР-373/22.03.2012 г.; КЦРР-714/05.06.2012 г.; КЦРР-1536/25.10.2012 |
20.11.2012 |
08.09.2012 |
Заличен |
1230 |
| L01AX03 |
Temozolomide |
L01AX03 Temozolomide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|